U.S. News & World Report - Tuesday, November 24, 2009
Author: Jeff Greer The University of Nebraska's Board of Regents took a stand on a controversial issue on Friday, voting down a resolution
that would have restricted the amount of
stemcellresearch
done in university facilities. The resolution, which needed five votes from the board and only got four, would have
followed former President George W. Bush's guidelines for researching
stemcells
, the Daily Nebraskan [http://www.dailynebraskan.com/news/regents-vote-against-limiting-
stem
-
cell
-
research
-1.2095586] reports.
University of Nebraska's current policy follows state and federal law for the
research
, the report says. The current policy has the support of the school's president, who spoke against the new resolution
before the regents voted last week. Student Regent Bradley Bohn tells the Daily Nebraskan that students at the Lincoln, Neb.,
school are "overwhelmingly in favor of continuing embryonic
research
."
One regent offered a personal experience as the main reason he voted against the resolution to change the school's policy.
"I had a young neighbor, a very young neighbor, who I watched go
through this until she passed away," Regent Bob Whitehouse
said. "In her dying moments, she said to me, 'Bob, please continue the research
.' It sticks with you. Is it one reason? Probably not. But it's compelling to an awful lot of folks with an awful lot
of hope along the way."
U.S. News & World Report - Tuesday, December 01, 2009
Author: Sarah Baldauf "I was so far down, I had to try," says Brent Benson, who entered a clinical trial last April to rejuvenate his failing
heart.
Stemcells
were taken from the 69-year-old biochemist's hip, processed over several weeks, and pumped as 30 separate injections
into parts of his heart muscle that were hibernating — not functioning well, yet not scarred and dead.
The ongoing study is one of many trials testing the ability of an adult's own
stemcells
— continuously produced and capable of becoming any of a range of
cell
types — to regenerate heart muscle and restore blood flow.
By one objective measure, Benson's heart has improved. In May, the main
pumping chamber of his heart was in distress,
enlarged to more than twice its normal size as it labored to compensate
for its dwindling strength. Benson was fatigued and
had trouble breathing. Six months later, the chamber had shrunk by a
third. The heart failure label can't be discarded — Benson's
heart is still weak. But he measures his improvement in his reclaimed
ability to do physical work, daily at his small farm
in Benjamin, Utah, and, in recent weeks, to winterize his family's
summer home, some 9,000 feet above sea level.
The lure of
stemcells
is seductive, but harnessing their ability to take on different roles is just beginning — as is measuring their effect.
Researchers often struggle to determine whether a patient's improvement can truly be attributed to a
stemcell
treatment. "There's such a high placebo effect," says Amit Patel, director of cardiovascular regenerative medicine at
the University of Utah and lead investigator in Benson's trial. It's likely that Benson's response is real, given that he
lives at such a high altitude, says Patel: "Elevation — that's the ultimate stress test."
No
stemcell
therapy will wipe out heart failure, experts warn. "Even as a wildly
optimistic guy, I don't imagine that anything I
do on a single day in the cath lab is going to reverse 30 years of
disease," says Douglas Losordo, director of the cardiovascular
regenerative medicine program at Northwestern University's Feinberg
School of Medicine. He is leading a small heart failure
pilot study using stemcells
extracted from a patient's own bloodstream.
A few of the unknowns in heart failure trials include how best to deliver the
stemcells
to the heart, precisely where to place them, and how to keep them from moving elsewhere, as many do. Researchers are
also studying which kinds of
stemcells
are most likely to work — those from a person's own bone marrow, blood, or the heart itself or, someday, "off the shelf"
stemcells
from other sources. "No evidence out there yet would point a person in one direction or another," Losordo says. It's
too new.
Across the spectrum of heart failure therapies, use of
stemcells
"is the sexiest one," says Patel, but it's "just one component of the entire continuum." To patients with failing hearts
and desperate for help, he suggests contacting a major
research
center that offers many weapons — from surgery to implantable devices to
stemcell
therapies.